C. HESDORFFER 4/93 
gene as a selectable marker in vitro and in vivo may lead to its 
use in protection of bone marrow cells from the toxicity of 
certain chemotherapeutic agents, which are inactivated by the 
presence of the MDR gene. These experiments may also provide 
insights into the use of the MDR gene as a selectable marker to 
increase the number of cells that also contain and potentially 
express a second non-selectable gene present in the retroviral 
vector such as MHC or 11-2. 
7. CONSULTANTS /COLLABORATORS : 
We will continue to collaborate with Dr. Stephen Goff 
(Columbia) who is an expert on retroviral vector design, 
retrovirus infection, and producer and packaging lines. 
Dr. John Dick (University of Toronto) will collaborate with us on 
studies involving the establishment of the bg/nu/xid immune- 
deficient mouse system and will provide breeding pairs of these 
mice . 
Drs. Michael Gottesman (National Cancer Institute) , Ira Pastan 
(National Cancer Institute) , and Susan Kane (City of Hope 
Hospital) will collaborate with us on studies using MDR 
retroviral vectors, PHaMDRl/a , and novel vectors being 
constructed . 
Drs. Peter Wiernik (Montefiore) and Subash Gulati (Sloan- 
Kettering) will collaborate with us on studies involving clinical 
trials detailed in this grant with the MDR and MHC genes. 
Letters of collaboration are attached for each of these 
collaborators . 
8 . LITERATURE CITED : 
1. Thomas ED, Buckner CD, Sanders J, et al. Lancet . 2:227- 
29, 1982. 
2. Lucarelli G, Izzi T, Polchi P, et al. J Exp Clin Cancer 
Res . 3:313-15, 1983. 
3. Lucarelli G, Galimberti M, Polchi P, et al. N Enal J 
Med . 322:417-21, 1990. 
4. Lucarelli G, Galimberti M, Polchi P, et al. In Bank A 
(Ed) : Sixth Cooley's Anemia Symposium . Annals of the 
New York Academy of Sciences, vol. 612, pp. 394-97. 
5. Herzig G. Hematology . 9:1-24, 1981. 
Recombinant DNA Research, Volume 18 
[ 111 ] 
